Somnuek SungkanuparphRebecca OyomopitoSunee SirivichayakulThira SirisanthanaPatrick C.K. LiPacharee KantipongChristopher K.C. LeeAdeeba KamarulzamanLiesl MesserschmidtMatthew G. LawPraphan PhanuphakMahidol UniversityChulalongkorn UniversityFoundation for AIDS ResearchResearch Institute for Health SciencesChiang Rai Regional HospitalKirby InstituteQueen Elizabeth Hospital Hong KongHospital Sungai BulohUniversity of MalayaFaculty of Medicine, Ramathibodi Hospital, Mahidol University2018-05-032018-05-032011-04-15Clinical Infectious Diseases. Vol.52, No.8 (2011), 1053-105715376591105848382-s2.0-79953837870https://repository.li.mahidol.ac.th/handle/20.500.14594/12541(See editorial commentary by Jordan on pages 1058-1060.)Of 682 antiretroviral-naïve patients initiating antiretroviral therapy in a prospective, multicenter human immunodeficiency virus type 1 (HIV-1) drug resistance monitoring study involving 8 sites in Hong Kong, Malaysia, and Thailand, the prevalence of patients with ≥1 drug resistance mutation was 13.8%. Primary HIV drug resistance is emerging after rapid scaling-up of antiretroviral therapy use in Asia. © 2011 The Author.Mahidol UniversityMedicineArticleSCOPUS10.1093/cid/cir107